Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shandong Boan Biotechnology Co., Ltd.
山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6955)

INSIDE INFORMATION ANNOUNCEMENT
PROFIT WARNING

This announcement is made by Shandong Boan Biotechnology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended 30 June 2026 (the "**Reporting Period**") and the information currently available to the Board, it is expected that the Group will record a net loss attributable to owners of the Company of approximately RMB79 million to RMB89 million for the Reporting Period, as compared to a net profit attributable to owners of the Company of approximately RMB21 million for the six months ended 30 June 2025.

The Board considers that the turnaround from profit to loss of the Group during the Reporting Period is mainly attributable to an increase in research and development expenditure incurred in connection with the acceleration of the Group's innovation strategy, with several of the Group's drug candidates advancing into clinical trials and key preclinical studies, including BA1106 (anti-CD25 monoclonal antibody), BA1302 (CD228-targeted ADC), BA1203 (PD-1/IL-2 antibody-cytokine prodrug), BA2201 (TL1A/IL-23p19 bispecific antibody) and BA1304 (EGFR/B7-H3 bispecific ADC). As a result, clinical trial expenses and research and development expenditures for these projects increased significantly during the Reporting Period.

As the Company is still in the course of finalizing the results of the Group for the Reporting Period, the information contained in this announcement is only based on the preliminary assessment made by the Board with reference to the Group's unaudited consolidated management accounts for the Reporting Period and the information currently available to the Board, which has neither been reviewed nor confirmed by the auditors of the Company or the audit committee of the Board. Shareholders and potential investors are advised to refer to the Group's interim results announcement for the Reporting Period, which is expected to be published on 27 August 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shandong Boan Biotechnology Co., Ltd.
Jiang Hua
Chairlady, Chief Executive Officer and
Executive Director

Yantai, the People's Republic of China, 14 August 2026

As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.